Inhibrx Biosciences, Inc. (INBX)
NasdaqGS · USD · Healthcare · Biotechnology
$88.61 (-5.11%) as of
Key statistics
- Market cap
- 1.30B
- Forward P/E
- -10.12
- EPS (TTM)
- -8.44
- Dividend yield
- 0.00%
- 52-week range
- 57.30 – 155.29
- Beta
- 3.82
- Profit margin
- 0.00%
- Analyst target
- $266.67
- Volume
- 251.18k
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- La Jolla, CA, United States
- Employees
- 109
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.